In a multicenter, randomized, double-blind, vehicle-controlled trial, 106 infants and children with mild to moderate atopic dermatitis applied hydrolipidic cream MAS063DP or vehicle three times a day to past, current, or “reasonable future” sites as monotherapy for 43 days (J. Pediatr. 2008;152:854–9). The mean age of subjects was 5 years.
One target lesion was chosen by investigators for evaluation and photography (mostly identified on extremities). Success was defined as reaching an IGA score of 0 (clear) or 1 (almost clear).
In an intention-to-treat analysis, 53 of 69 subjects (77%) in the hydrolipidic cream group achieved a score of 0 or 1 at day 22, compared with none in the vehicle group.
Dr. Krakowski disclosed having had no relevant conflicts of interest.
Several FDA-approved products relieve the atopic dermatitis symptoms of stinging, burning, and pruritus. Courtesy Dr. Andrew C. Krakowski